Results 111 to 120 of about 36,741 (290)

Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo T2DM study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This real‐world study evaluated the effectiveness and safety of switching basal insulin (BI) to insulin glargine 300 U/mL (Gla‐300) in adults with inadequately controlled type 2 diabetes mellitus (T2DM), previously receiving basal‐supported oral therapy plus prandial insulin (BOTplus) or multiple (≥3) daily injections (MDI) of short ...
Stefan Pscherer, Andreas Fritsche, Helmut Anderten, Katrin Pegelow, Henry Y. Han, Martin Pfohl, Jochen Seufert   +6 more
wiley   +1 more source

Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Imeglimin is a novel oral hypoglycemic agent approved for the treatment of type 2 diabetes in Japan, with dual actions to enhance insulin secretion and improve insulin sensitivity, suggested by preclinical evidence. However, the effect of imeglimin on tissue‐specific insulin sensitivity and glucose kinetics using glucose tracers is ...
Tsubasa Tajima, Hideyoshi Kaga, Naoaki Ito, Toshiki Kogai, Hitoshi Naito, Saori Kakehi, Satoshi Kadowaki, Yuya Nishida, Ryuzo Kawamori, Yoshifumi Tamura, Hirotaka Watada   +10 more
wiley   +1 more source

Pharmacoeconomic evaluation of oral-hypoglycemic agents at hospital in Bangalore

, 2015
Iosr Journals, Abdelaziz Msl, HG Shobha Rani, S. Ravindranath, Ramjan Shaik, Mohamed Kasim, Anas abdul Salam   +6 more
openalex   +1 more source

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz, Aidan Shulkin, Asmaa Housni, Amélie Roy‐Fleming, Rémi Rabasa‐Lhoret, Jean‐Francois Yale, Michael A. Tsoukas, Tricia M. Peters, Anne‐Sophie Brazeau   +8 more
wiley   +1 more source

Navigating Prediabetes in a Foreign Country: A Qualitative Study of Self‐Management Experiences Among Chinese‐Speaking Immigrants in Australia

Journal of Advanced Nursing, EarlyView.
ABSTRACT Aim Chinese‐speaking immigrants in Australia have a higher risk of type 2 diabetes and face more barriers to accessing quality healthcare compared to non‐culturally and linguistically diverse populations. This study aimed to explore the self‐management experiences of Chinese‐speaking Australians with self‐reported lived experience of ...
Min Zhang, Kirsten J. Coppell, Johnny Lo, Lisa Whitehead   +3 more
wiley   +1 more source

Cost analysis study of oral hypoglycemic agents available in Nepalese market

, 2015
Binaya Shrestha
openalex   +2 more sources

Incidence of treatment intensification based on HbA1c trends in people with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
We conducted this study to examine the incidence of treatment intensification in response to changes in the HbA1c levels in people with type 2 diabetes. Of the 5,683 patients, 4,553 (80.1%) did not undergo treatment intensification at the second consultation.
Erika Sugito, Takehiro Sugiyama, Ryotaro Bouchi, Akiyo Tanabe, Kohjiro Ueki, Mitsuru Ohsugi   +5 more
wiley   +1 more source

Efficacy and safety of SGLT2 inhibitor on insulin resistance and hyperglycemia in Werner syndrome—A case report

Journal of Diabetes Investigation, EarlyView.
Dapagliflozin improved glycemic control and insulin resistance while preserving skeletal muscle mass, body weight, and renal function over 2 years in a patient with Werner syndrome. These findings suggest that SGLT2 inhibitors may be used safely with beneficial effects in patients with Werner syndrome.
Takashi Yagi, Daisuke Aotani, Chie Hasegawa, Yuki Shimizu, Hiroyuki Koyama, Yoshiro Maezawa, Koutaro Yokote, Tomohiro Tanaka   +7 more
wiley   +1 more source

Analysis of oral hypoglycemic agents in the normative documents regulating the treatment of diabetes mellitus 2 type

, 2016
L. V. Yakovleva, A. L. Bilyk
openalex   +2 more sources

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent [PDF]

, 2015
Yunzhao Tang, Gang Wang, Zhenhuan Jiang, Tiantian Yan, Yijun Chen, Min Yang, Lingling Meng, Yanjuan Zhu, Chenguang Li, Li Zhu, Ping Yü, Changlin Ni   +11 more
openalex   +1 more source